CIT GAP Funds invest in EVS Glaucoma Therapeutics
The Center for Innovative Technology said Wednesday that its CIT GAP Funds has invested in EVS Glaucoma Therapeutics. Financial terms weren't announced. Herndon, Va.-based EVS is developing a sustained delivery system for glaucoma medication.
11 September 2013•3 mins read
